Neurogene Highlights Gene Therapy Advancements in New Update

Neurogene ( (NGNE) ) has provided an announcement.

On June 9, 2025, Neurogene Inc. updated its corporate presentation, highlighting its innovative approaches in gene therapy for neurological disorders. The company emphasized its internal manufacturing capabilities and strategic pipeline flexibility, particularly for its NGN-401 program targeting Rett syndrome, which is currently in Phase 1/2 clinical trials. This development positions Neurogene to potentially address significant unmet medical needs and capitalize on attractive market opportunities.

The most recent analyst rating on (NGNE) stock is a Buy with a $45.00 price target. To see the full list of analyst forecasts on Neurogene stock, see the NGNE Stock Forecast page.

Spark’s Take on NGNE Stock

According to Spark, TipRanks’ AI Analyst, NGNE is a Underperform.

Neurogene’s overall score is primarily influenced by its financial performance, which is challenged by zero revenues and significant net losses. While the stock shows some technical strength, the high beta and potential overbought conditions pose risks. The valuation reflects the speculative nature of investing in an early-stage biotech firm.

To see Spark’s full report on NGNE stock, click here.

More about Neurogene

Neurogene Inc. operates in the biopharmaceutical industry, focusing on developing therapies for complex neurological diseases. The company utilizes its proprietary EXACT technology to address limitations in conventional gene therapy and has a strategic focus on conditions like Rett syndrome.

Average Trading Volume: 275,881

Technical Sentiment Signal: Sell

Current Market Cap: $311.3M

For detailed information about NGNE stock, go to TipRanks’ Stock Analysis page.